For example, dasatinib, an oral BCR-ABL TKI, is approved for chronic myeloid leukemia [7], Philadelphia-positive leukemia [8], chronic myeloproliferative disorders with PDGFRβ rearrangements [9], some mast cell leukemias (MCL) with noncanonical KIT mutations [10], and KIT-positive AML [11]. This evidence concerns the gene KIT and chronic myelogenous leukemia, BCR-ABL1 positive.